IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"
IGC Pharma (NYSE American: IGC) announced on March 12, 2025, that Ascendiant Capital Markets has released a coverage report following IGC's Q3 results. The report suggests potential positive clinical data in 2025 could serve as strong catalysts for the stock. Notably, Ascendiant has raised their price target to $4.25.
The company clarified that analyst reports represent the views of those analysts exclusively and not necessarily those of IGC Pharma. IGC emphasized it is not responsible for the content, accuracy, or timelines provided by analysts.
IGC Pharma (NYSE American: IGC) ha annunciato il 12 marzo 2025 che Ascendiant Capital Markets ha pubblicato un rapporto di copertura a seguito dei risultati del terzo trimestre di IGC. Il rapporto suggerisce che potenziali dati clinici positivi nel 2025 potrebbero fungere da forti catalizzatori per le azioni. È importante notare che Ascendiant ha alzato il proprio obiettivo di prezzo a $4,25.
La società ha chiarito che i rapporti degli analisti rappresentano esclusivamente le opinioni di quegli analisti e non necessariamente quelle di IGC Pharma. IGC ha sottolineato di non essere responsabile per il contenuto, l'accuratezza o le tempistiche fornite dagli analisti.
IGC Pharma (NYSE American: IGC) anunció el 12 de marzo de 2025 que Ascendiant Capital Markets ha publicado un informe de cobertura tras los resultados del tercer trimestre de IGC. El informe sugiere que datos clínicos positivos potenciales en 2025 podrían servir como fuertes catalizadores para la acción. Cabe destacar que Ascendiant ha elevado su objetivo de precio a $4.25.
La compañía aclaró que los informes de los analistas representan exclusivamente las opiniones de esos analistas y no necesariamente las de IGC Pharma. IGC enfatizó que no es responsable por el contenido, la precisión o los plazos proporcionados por los analistas.
IGC Pharma (NYSE American: IGC)는 2025년 3월 12일 Ascendiant Capital Markets가 IGC의 3분기 결과에 대한 커버리지 보고서를 발표했다고 알렸습니다. 이 보고서는 2025년에 긍정적인 임상 데이터가 주식의 강력한 촉매제가 될 수 있음을 시사합니다. 특히, Ascendiant는 목표 주가를 $4.25로 상향 조정했습니다.
회사는 분석가 보고서가 해당 분석가들의 의견만을 반영하며 IGC Pharma의 의견이 아님을 명확히 했습니다. IGC는 분석가들이 제공한 내용, 정확성 또는 일정에 대해 책임을 지지 않는다고 강조했습니다.
IGC Pharma (NYSE American: IGC) a annoncé le 12 mars 2025 que Ascendiant Capital Markets a publié un rapport de couverture suite aux résultats du troisième trimestre d'IGC. Le rapport suggère que des données cliniques positives potentielles en 2025 pourraient servir de forts catalyseurs pour l'action. Notamment, Ascendiant a relevé son objectif de prix à $4,25.
La société a précisé que les rapports des analystes représentent uniquement les opinions de ces analystes et non nécessairement celles d'IGC Pharma. IGC a souligné qu'elle n'est pas responsable du contenu, de l'exactitude ou des délais fournis par les analystes.
IGC Pharma (NYSE American: IGC) gab am 12. März 2025 bekannt, dass Ascendiant Capital Markets einen Coverage-Bericht veröffentlicht hat, der auf den Ergebnissen des dritten Quartals von IGC basiert. Der Bericht deutet darauf hin, dass potenziell positive klinische Daten im Jahr 2025 als starke Katalysatoren für die Aktie dienen könnten. Bemerkenswert ist, dass Ascendiant ihr Kursziel auf $4,25 angehoben hat.
Das Unternehmen stellte klar, dass Analystenberichte ausschließlich die Ansichten dieser Analysten widerspiegeln und nicht notwendigerweise die von IGC Pharma. IGC betonte, dass es nicht für den Inhalt, die Genauigkeit oder die von den Analysten bereitgestellten Zeitpläne verantwortlich ist.
- Analyst raises price target to $4.25
- Potential positive clinical data catalysts expected in 2025
- None.
POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage report entitled "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to
All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.
A copy of the updated report can be obtained directly from Ascendiant Capital Markets: LINK
About IGC Pharma (dba IGC):
IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia ("CALMA") associated with Alzheimer's (clinicaltrials.gov, IGC Pharma Phase II). Interim data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 32 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions. The Company operates a wellness brand offering scientifically formulated products under the brand Holiby™ and as white-labeled formulations.
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ("SEC") filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian / Walter Frank
IMS Investor Relations
igc@imsinvestorrelations.com
(203) 972-9200
SOURCE: IGC Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new price target for IGC stock according to Ascendiant Capital Markets?
What catalysts does Ascendiant Capital Markets identify for IGC stock in 2025?
When did Ascendiant Capital Markets release their latest coverage report on IGC?
What was the context of Ascendiant's new coverage report on IGC?
